Cambium Bio (ASX:CMB) Price-to-Owner-Earnings : (As of Dec. 16, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Price-to-Owner-Earnings?

As of today (2024-12-16), Cambium Bio's share price is A$0.44. Cambium Bio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for Cambium Bio's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Cambium Bio was 1127.82. The lowest was 0.43. And the median was 6.85.

ASX:CMB's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 31.405
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-12-16), Cambium Bio's share price is A$0.44. Cambium Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.54. Therefore, Cambium Bio's PE Ratio (TTM) for today is At Loss.

As of today (2024-12-16), Cambium Bio's share price is A$0.44. Cambium Bio's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.54. Therefore, Cambium Bio's PE Ratio without NRI for today is At Loss.

During the past 11 years, Cambium Bio's highest PE Ratio without NRI was 12.57. The lowest was 0.00. And the median was 6.72.

Cambium Bio Price-to-Owner-Earnings Historical Data

The historical data trend for Cambium Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Price-to-Owner-Earnings Chart

Cambium Bio Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Price-to-Owner-Earnings

Get a 7-Day Free Trial

10.83

Cambium Bio Semi-Annual Data
	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
Price-to-Owner-Earnings	Get a 7-Day Free Trial						-	10.83	-	-	-

Competitive Comparison of Cambium Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cambium Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Price-to-Owner-Earnings falls into.

Cambium Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cambium Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	0.44	/	-0.54
	=

Cambium Bio (ASX:CMB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Cambium Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.cambium.bio

Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines